Clinical Trial: Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration

U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT06991790) titled 'Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration' on May 07.

Brief Summary: The goal of this study is to explore the efficacy and safety of sacituzumab govitecan in combination with toripalimab as first - line treatment in patients with advanced triple - negative breast cancer.

The main questions it aims to answer are:

1. To investigate the efficacy and safety of sacituzumab govitecan in combination with toripalimab as first - line treatment for advanced triple - negative breast cancer.

2. To explore the biomarkers that can predict the efficacy of sa...